Tag: Avibactam

In a 2024 study, the combination of ceftazidime/avibactam plus meropenem showed remarkable synergistic activity against carbapenem-resistant *Klebsiella pneumoniae*. This specific, advanced combination therapy addresses the critical question: **Can ceftazidime and meropenem be given together?**

Antibiotic resistance caused by bacteria producing β-lactamase enzymes poses a significant and increasing global public health threat. Understanding which of the following is a β-lactamase inhibitor is vital, as these agents are designed to counteract this resistance, preserving the effectiveness of a major class of antibiotics.

Antimicrobial resistance is a global health threat that was associated with nearly 5 million deaths in 2019 [1.5.4]. A key strategy to combat this is understanding **what is the mechanism of action of a beta-lactamase inhibitor**, which protects crucial antibiotics from bacterial defenses [1.2.1, 1.2.2].

According to a 2025 study in the *European Journal of Clinical Microbiology & Infectious Diseases*, infections caused by multi-drug-resistant Gram-negative bacteria continue to be a serious global health problem. In this context, understanding the role of advanced treatments, such as what is AVI medication—specifically the combination drug ceftazidime-avibactam—is crucial for combating these difficult-to-treat pathogens.

Over 2.8 million antibiotic-resistant infections occur in the U.S. each year, highlighting a critical threat to modern medicine. Understanding **how do beta lactamase inhibitors work** is key to combating this resistance and preserving the efficacy of vital beta-lactam antibiotics.